Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance
Find Stocks Now

Teladoc's (NYSE:TDOC) Q1 Sales Top Estimates But Quarterly Guidance Underwhelms

Published 04/25/2024, 04:11 PM
Updated 04/25/2024, 04:32 PM
Teladoc's (NYSE:TDOC) Q1 Sales Top Estimates But Quarterly Guidance Underwhelms

Digital medical services platform Teladoc Health (NYSE:TDOC) announced better-than-expected results in Q1 CY2024, with revenue up 2.7% year on year to $646.1 million. On the other hand, next quarter's revenue guidance of $647.5 million was less impressive, coming in 2.3% below analysts' estimates. It made a GAAP loss of $0.49 per share, down from its loss of $0.42 per share in the same quarter last year.

Is now the time to buy Teladoc? Find out by reading the original article on StockStory, it's free.

Teladoc (TDOC) Q1 CY2024 Highlights:

  • Revenue: $646.1 million vs analyst estimates of $637.4 million (1.4% beat)
  • EPS: -$0.49 vs analyst expectations of -$0.47 (3.9% miss)
  • Revenue Guidance for Q2 CY2024 is $647.5 million at the midpoint, below analyst estimates of $662.6 million
  • The company reconfirmed its revenue guidance for the full year of $2.69 billion at the midpoint
  • Gross Margin (GAAP): 69.9%, in line with the same quarter last year
  • Free Cash Flow was -$26.59 million, down from $128.7 million in the previous quarter
  • US Integrated Care Members: 91.8 million, up 6.9 million year on year
  • Market Capitalization: $2.32 billion

Founded to help people in rural areas get online medical consultations, Teladoc Health (NYSE:TDOC) is a telemedicine platform that facilitates remote doctor’s visits.

Online MarketplaceMarketplaces have existed for centuries. Where once it was a main street in a small town or a mall in the suburbs, sellers benefitted from proximity to one another because they could draw customers by offering convenience and selection. Today, a myriad of online marketplaces fulfill that same role, aggregating large customer bases, which attracts commission-paying sellers, generating flywheel scale effects that feed back into further customer acquisition.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Sales GrowthTeladoc's revenue growth over the last three years has been strong, averaging 28.7% annually. This quarter, Teladoc beat analysts' estimates but reported lacklustre 2.7% year-on-year revenue growth.

Teladoc is expecting next quarter's revenue to decline 0.8% year on year to $647.5 million, a reversal from the 10.1% year-on-year increase it recorded in the comparable quarter last year. Ahead of the earnings results, analysts were projecting sales to grow 3% over the next 12 months.

Usage Growth As an online marketplace, Teladoc generates revenue growth by increasing both the number of users on its platform and the average order size in dollars.

Over the last two years, Teladoc's users, a key performance metric for the company, grew 7.8% annually to 91.8 million. This is decent growth for a consumer internet company.

In Q1, Teladoc added 6.9 million users, translating into 8.1% year-on-year growth.

Revenue Per UserAverage revenue per user (ARPU) is a critical metric to track for consumer internet businesses like Teladoc because it measures how much the company earns in transaction fees from each user. Furthermore, ARPU gives us unique insights as it's a function of a user's average order size and Teladoc's take rate, or "cut", on each order.

Teladoc's ARPU growth has been mediocre over the last two years, averaging 2.7%. However, the company's ability to continue increasing prices while growing its users shows they still find value in its platform. This quarter, ARPU declined 5% year on year to $7.04 per user.

Key Takeaways from Teladoc's Q1 Results It was good to see Teladoc narrowly top analysts' revenue and EBITDA expectations this quarter. Although next quarter's revenue guidance was softer than expected, its full-year sales outlook was in line. Furthermore, its full-year free cash flow and U.S. Integrated Care Member estimates beat Wall Street's estimates. Overall, this was a decent quarter for Teladoc. The stock is up 4.2% after reporting and currently trades at $13.89 per share.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.